FundaMental Pharma will present its lead clinical candidate FMP374, a novel dual-acting NMDAR modulator, at the Bio-Neuroscience Conference in Amsterdam on Wednesday, 25 February at 16:45 CET. The presentation will highlight the scientific foundation and preclinical data supporting the drug’s advancement toward IND-enabling studies for treatment-resistant depression.
FMP374 is designed to address treatment-resistant depression (TRD), which affects over 30% of patients with major depressive disorders who do not respond to at least two different antidepressants. According to the company, NMDAR is the most compelling clinically validated target for TRD.
The drug works through a distinctive mechanism: these dual-acting molecules uniquely disrupt the complex formed between NMDAR and the transient receptor potential cation channel subfamily M member 4 (TRPM4), while simultaneously acting as potent NMDAR antagonists. Dr. Dirk Beher, Chief Executive Officer of FundaMental Pharma, will deliver the presentation, discussing the innovative, neurobiology-driven approach the company aims to use to redefine the treatment paradigm for TRD and meaningfully improve outcomes for patients with severe unmet medical needs.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.benzinga.com/pressreleases/26/02/g50641631/fundamental-pharma-to-showcase-groundbreaking-approach-to-treatment-resistant-depression-at-bio-ne